Renal Damage Articles & Analysis
3 news found
- OXLUMO Now Indicated for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary and Plasma Oxalate Levels in Pediatric and Adult Patients - - Approval is Based on Positive Efficacy and Safety Results of the ILLUMINATE-C Phase 3 Study of OXLUMO in PH1 Patients with Severe Renal Impairment, Including Those on Hemodialysis - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 6, 2022-- Alnylam ...
"It enables our team to identify metabolomic safety biomarkers of drug-induced renal toxicity and the mechanisms by which these toxicities occur. This research will lead us to identifying at-risk patients and exploring the use of concomitantly administered medicines as protectants against drug-induced renal damage. ...
WHO representative in Sri Lanka, Firdosi Rastam Mehta, told SciDev.Net that a new form of chronic kidney disease unlinked to diabetes mellitus, hypertension, kidney damage or other known causes, has emerged in the identified areas. The new disease has been characterised as "slowly progressive, probably starting in the second decade of life, and asymptomatic (without apparent ...